Opus Genetics
IRD
Opus Genetics (IRD) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.12
- EPS estimate
- −$0.21
- EPS surprise
- +41.46%
- Revenue surprise
- −28.84%
- Revenue
- $2.9M
- Revenue estimate
- $4.0M
- Reported
- Aug 13, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 13, 2025 | −$0.21 | −$0.12 | +41.46% | $2.9M | SEC |
| Q1 2025 | May 15, 2025 | −$0.25 | −$0.24 | +4.00% | $4.4M | SEC |
| Q4 2024 | Mar 31, 2025 | −$0.25 | −$1.27 | −418.37% | $4.3M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.24 | −$0.29 | −22.11% | $3.9M | SEC |
| Q2 2024 | Aug 13, 2024 | −$0.26 | −$0.30 | −17.65% | $1.1M | SEC |
| Q1 2024 | May 10, 2024 | −$0.11 | −$0.29 | −163.64% | $1.7M | SEC |
| Q4 2023 | Mar 8, 2024 | −$0.05 | −$0.21 | −300.00% | $1.7M | SEC |
| Q3 2023 | Nov 13, 2023 | −$0.22 | $0.25 | +212.61% | $11.9M | SEC |
| Q2 2023 | Aug 11, 2023 | −$0.23 | −$0.24 | −6.19% | $3.7M | SEC |
| Q1 2023 | May 15, 2023 | −$0.15 | −$0.28 | −81.82% | $1.7M | SEC |
| Q4 2022 | Mar 30, 2023 | $1.32 | $1.58 | +20.15% | $39.9M | SEC |
| Q3 2022 | Nov 4, 2022 | −$0.28 | −$0.22 | +21.99% | $0.00 | SEC |
| Q2 2022 | Aug 12, 2022 | −$0.33 | −$0.25 | +24.70% | $0.00 | SEC |
| Q1 2022 | May 13, 2022 | −$0.35 | −$0.35 | +0.00% | $0.00 | SEC |
| Q4 2021 | Mar 24, 2022 | −$0.29 | −$0.35 | −21.53% | $0.00 | SEC |
| Q3 2021 | Nov 12, 2021 | −$0.36 | −$0.25 | +30.17% | $489,000.00 | SEC |
| Q2 2021 | Aug 12, 2021 | −$0.38 | −$0.52 | −35.95% | $100,000.00 | SEC |
| Q1 2021 | May 7, 2021 | −$0.71 | −$3.57 | −401.05% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Opus Genetics (IRD) last report earnings?
Opus Genetics last reported on Aug 13, 2025, covering fiscal Q2 2025.
Did IRD beat earnings estimates?
Yes. Opus Genetics reported EPS of −$0.12 for Q2 2025 against a −$0.21 estimate — a 41.46% beat.
How much revenue did IRD report last quarter?
Opus Genetics reported $2.9M in revenue for Q2 2025, against a consensus estimate of $4.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.